Keynote speakers
Dr Michael Cox
Founder and Principal, Martian Clinical Consulting
Speaker Bio
Michael Cox, Pharm.D., M.H.Sc., BCOP
Dr. Michael Craig Cox is the founder and Principal of Martian Clinical Consulting, an independent consultancy specializing in oncology drug development strategy with a particular focus on pediatric cancer.
With more than 20 years of experience across large pharma, mid-size, and startup biotechnology companies, Dr. Cox is one of a small number of industry leaders with deep, hands-on expertise in both pediatric and adult precision oncology — having shepherded multiple molecularly targeted therapies through clinical development and global regulatory approval for children and adults alike.
Dr. Cox has played an instrumental role in the clinical development and regulatory approvals of multiple landmark oncology agents, including tovorafenib (Ojemda™), selpercatinib (Retevmo®), larotrectinib (VITRAKVI®), radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®), cetuximab (ERBITUX®), denosumab (XGEVA®), and darbepoetin alfa (Aranesp®). His work has spanned pediatric and adult populations, with particular expertise in molecularly targeted, tissue-agnostic, and small molecule kinase inhibitor programs.
Prior to founding Martian Clinical Consulting, Dr. Cox served as Senior Vice President, Head of Early Development at Circle Pharma, where he built a 20-person development organization and led the first clinical-stage program from development candidate selection. Before joining Circle, he served as Vice President of Clinical Development at Day One Biopharmaceuticals, where he led the pediatric development program for tovorafenib.
Earlier in his career, he held global and regional clinical development and medical affairs positions of increasing responsibility at Loxo Oncology (acquired by Eli Lilly & Co.), Bayer Consumer Care AG (Basel, Switzerland), Merck KGaA (Darmstadt, Germany), and Amgen, Inc.
Dr. Cox has published abstracts and manuscripts in journals including The New England Journal of Medicine, Lancet Oncology, the Journal of Clinical Oncology, Cancer, and Clinical Cancer Research. He is a member of numerous cancer research organizations including the American Association of Cancer Research, the American Society of Clinical Oncology, and the European Society of Medical Oncology.
Dr. Cox earned his Pharm.D. from Ohio Northern University’s Raabe College of Pharmacy and an MHSc in Clinical Research from Duke University’s School of Medicine. He completed pharmacy practice residencies at Mission Hospitals (Asheville, NC) and the University of Pittsburgh Cancer Institute (Pittsburgh, PA), followed by a clinical drug development fellowship in the Clinical Pharmacology Section of the Center for Cancer Research at the National Cancer Institute (Bethesda, MD). He is a Board-Certified Oncology Pharmacist (BCOP).
Dr Michael Harhay
Deputy Director of the Division of Epidemiology and Director of the Center for Clinical Trials Innovation, University of Pennslyvannia
Speaker Bio
Dr. Michael Harhay is an Associate Professor of Epidemiology, Medicine, and Statistics and Data Science at the University of Pennsylvania, where he serves as Deputy Director of the Division of Epidemiology and Director of the Center for Clinical Trials Innovation (CCTI).
His PCORI- and NIH-funded research focuses on improving the design, conduct, and reporting of clinical trials, bridging methodological innovation with practical application to help researchers adopt rigorous, modern approaches.
He is Deputy Editor of the American Journal of Respiratory and Critical Care Medicine and the recipient of the 2025 Jo Rae Wright Award for Outstanding Science from the American Thoracic Society.
Dr Marylyn Ritchie
Chief AI Officer, and Director AI Center for Health Innovation and Informatics, Medical University of South Carolina
Speaker Bio
Dr. Marylyn D. Ritchie is the Chief Artificial Intelligence Officer for the MUSC Enterprise, Director of the MUSC AI Center for Health Innovation and Informatics, as well as Associate Dean for Artificial Intelligence and Director of the Division of Computational Health Sciences and Al in the College of Medicine at the Medical University of South Carolina (MUSC). Dr. Ritchie is also the SmartState Endowed Chair in Translational Biomedical Informatics. Dr. Ritchie is an expert in translational bioinformatics, with a focus on developing, applying, and disseminating algorithms, methods, and tools integrating electronic health records (EHR) with genomics. Dr. Ritchie has over 20 years of experience in translational bioinformatics and has authored over 500 publications. Dr. Ritchie was appointed as a Fellow of the American College of Medical Informatics (ACMI) in 2020. Dr. Ritchie was elected as a member of the National Academy of Medicine in 2021. Dr. Ritchie was a member of the ELAM class of 2022.
In her new role, Dr. Ritchie is developing the AI strategy across MUSC. She is leading enterprise-wide strategies to harness AI in support of the institution’s tripartite mission of education, research, and patient care. She is focused on building collaborative AI initiatives that connect clinicians, faculty, industry partners, staff, students, and trainees to drive innovation at MUSC.
Dr Kim Sutherland
Executive Director, Office for Health and Medical Research, NSW Health
Speaker Bio
Dr Kim Sutherland leads the Office for Health and Medical Research. Prior to her appointment to OHMR, she held Director roles at the Agency for Clinical Innovation and the Bureau of Health Information. Kim is a health services researcher with experience in performance measurement and reporting, evaluation and assessment of quality, and change management in healthcare organisations. She played a central role in the development of performance measurement frameworks in NSW and the UK and co-authored a series of reports on the English NHS quality agenda. Kim holds a Master of Science from London Hospital Medical College, a Master of Business Administration from Imperial College London and a PhD from the University of Cambridge. In 2022, Kim received the Public Service Medal for outstanding public service to NSW Health.
Professor Adam Jaffe
John Beveridge Professor and co-head of Paediatrics and Child Health at UNSW, Sydney
Speaker Bio
Professor Adam Jaffe is the John Beveridge Professor and co-head of Paediatrics and Child Health at UNSW, Sydney, and head of the respiratory department at Sydney Children’s Hospital Randwick. Jaffe has expertise in rare diseases and chairs the Scientific and Medical Advisory Committee of Rare Voices Australia. He contributed to the writing of the National Strategic Action Plan for Rare Diseases and the National Recommendations for Rare Disease Health Care. Jaffe has is a steering committee member of the Rare Diseases International Western Pacific Taskforce and previously the International Rare Disease Research Consortium n of 1 Taskforce. Jaffe established the molecular and integrative precision medicine centre for cystic fibrosis at UNSW Sydney and was a lead investigator for the Luminesce Alliance Cystic Fibrosis Functional Genomics Project.
Tiffany Boughtwood
Australian Health Genomics Commissioner, Genomics Australia
Speaker Bio
Tiffany Boughtwood is the inaugural Australian Health Genomics Commissioner, guiding the work of Genomics Australia and providing advice to Government based on broad engagement with the genomics sector and community.
Tiffany has 30 years’ experience in molecular biology and management: leading academic and diagnostic genomic programs; collaborating internationally in genomic research; and consulting in health genomic implementation.
She was the Managing Director of Australian Genomics, a national collaborative supporting genomic research and its translation into clinical practice. She served on the World Economic Forum Global Future Council for Biotechnology and the WHO Collective Global Network for Rare Disease. Tiffany is a member of the WHO Technical Advisory Group on Genomics, is on the Strategic Leadership Committee for the Global Alliance for Genomics and Health, and is an International Advisor to the MyGenom Project Malaysia.
Speakers
Professor Hilda Pickett
Head of the Telomere Length Regulation Unit at Children’s Medical Institute (CMRI), and Professor in the Faculty of Medicine and Health at The University of Sydney
Speaker Bio
Professor Hilda Pickett is Head of the Telomere Length Regulation Unit at Children’s Medical Institute (CMRI), Sydney, Australia, and Professor in the Faculty of Medicine and Health at the University of Sydney. She obtained her PhD from the Department of Genetics at the University of Leicester, and completed postdoctoral positions at Cancer Research UK, St James’s University Hospital, Leeds, and in the Cancer Research Unit at CMRI, prior to establishing her lab at CMRI. Her research focuses on the mechanisms that maintain telomere integrity and drive cellular immortalisation, with a particular emphasis on the Alternative Lengthening of Telomeres (ALT) pathway in cancer. Professor Pickett has made seminal contributions to understanding ALT biology, including the discovery of key molecular dependencies that have enabled the development of the first targeted therapeutic strategies for ALT cancers. Her work spans fundamental mechanistic research through to translation. She is an inventor on multiple international patents and co-founder of Tessellate Bio, a biotechnology company developing novel precision oncology therapies.
Professor Robyn Jamieson
Director, Eye Genetics Research Unit, Children's Medical Research Institute
Speaker Bio
Professor Robyn Jamieson leads the Eye Genetics Research Unit at Children's Medical Research Institute, and heads the Eye Genetics Clinic at The Children’s Hospital at Westmead. She is also Head of the Western Sydney Genetics Program, The Children’s Hospital at Westmead, and Head, Speciality of Genomic Medicine, University of Sydney.
She has established a research program dedicated to understanding molecular mechanisms contributing to developmental eye disorders and genetic retinal diseases. Her research has successfully translated to the availability of clinical genomic diagnostics and clinical trials and therapy in these conditions. The aim of Professor Jamieson’s current research is to develop detailed understanding of the role of retinal disease genes causing blindness, and to use genome engineering, cellular and vector technologies for novel treatments for these conditions.
The aim of Professor Jamieson’s current research is to develop detailed understanding of the role of retinal disease genes causing blindness, and to use genome engineering, cellular and vector technologies for novel treatments for these conditions.
Professor Tracy Bryan
Head of the Cell Biology Unit at Children’s Medical Research Institute (CMRI) and Professor in the Faculty of Medicine and Health, University of Sydney
Speaker Bio
Professor Tracy Bryan is Head of the Cell Biology Unit at Children’s Medical Research Institute (CMRI) and Professor in the Faculty of Medicine and Health, University of Sydney. Professor Bryan is a biochemist and cell biologist who has been active in the telomere field since 1993, and has made fundamental discoveries in the field, such as the discovery of the Alternative Lengthening of Telomeres (ALT) mechanism in human cancers, and the discovery of a new gene mutated in Telomere Biology Disorders, ACD. In recognition of these discoveries, she was the inaugural recipient of the ACGT Award (the Australian Cell cycle, Genome stability and Telomere biology award) in 2023. She received a PhD from University of Sydney in 1997, receiving the Peter Bancroft Prize for research. She carried out postdoctoral research with Nobel Laureate Thomas Cech in Colorado, returning to establish her laboratory at CMRI in 2001. The research in Professor Bryan’s laboratory focusses on the role of telomerase, the enzyme that maintains telomeres, in cancer and in bone marrow failure syndromes.
Dr Teresa Anderson
Chief Executive Single Digital Patient Record Implementation Authority
Speaker Bio
Dr Teresa Anderson has more than 35 years of extensive experience as a senior health service manager. She has a well-established reputation for implementing strategies focused on fostering partnerships, supporting the delivery of innovative, patient centred, best practice health care.
Dr Anderson was the Chief Executive of Sydney Local Health District for over 13 years.
She is a Speech Pathologist, internationally recognised for her specialist knowledge and skills in the research, assessment and management of paediatric and adult dysphagia, early communication development, early childhood development and early intervention.
She is a member of the Australian Eating Disorders, Research and Translation Centre Governing Council, a board member of the Centre for Primary Health Care Equity and the Institute of Public Administration Australia NSW.
In the 2018 Queen’s Birthday Honours, Dr Anderson was made a Member of the Order of Australia for her service to community health and to public administration in NSW as a clinician, manager and health service executive.
Professor Wendy Gold
Head of School, Faculty of Medicine and Health, University of Sydney, and group leader of the Molecular Neurobiology Research group at Kids Research, The Children’s Hospital, Westmead.
Speaker Bio
Professor Wendy Gold
Wendy Gold is a Professor at the University of Sydney and leads a research team at The Children’s Hospital at Westmead in Sydney. She trained in genetics, completing both an Honours degree and a PhD.
Her work focuses on conditions that affect how the brain develops in children, including Rett syndrome and CDKL5 Deficiency Disorder. Professor Gold’s goal is to better understand these conditions, to discover biomarkers that will inform and guide future clinical trials and to help develop new treatments that improve the lives of affected children and their families.
Her team studies patient cells in the lab, including specialised brain cells grown from skin or blood samples. They also use small “mini-brain” models to better understand how the brain develops and what goes wrong in these conditions. This research helps identify early signs of disease and test potential therapies, including gene therapy approaches that aim to correct faulty genes.
Professor Gold’s work brings together experts from many areas, including brain science, medicine, and drug development. With over 17 years of experience, she has contributed to major advances in understanding rare childhood brain disorders and is actively working towards safer and more effective treatments.
Professor Mark Cowley
Deputy Director, Enabling Platforms & Collaboration and Group Leader, Children’s Cancer Institute
Speaker Bio
Professor Mark Cowley is Deputy Director, Enabling Platforms and Collaboration at Children’s Cancer Institute (CCI) and Conjoint Associate Professor, Faculty of Medicine and Health, UNSW Sydney.
He joined CCI in 2018 to head the Computational Biology Group, and is also a Lead Investigator and co-head of the Luminesce Alliance Data Enabling Platform, president of AGTA (peak genomics body in the region) co-head of the ACRF Child Cancer Liquid Biopsy Program and a member of Rare Diseases NSW.
Mark is the Genome Informatics and Data Enabling Platforms lead for the Zero Childhood Cancer Program, overseeing creation of novel analytical approaches and systems that enable real-time analysis of Whole Genome, Transcriptome and Methylome data for every childhood cancer patient in Australia. Mark has been an early adopter of sequencing methods in Australia, establishing some of the world’s first clinically accredited WGS-based diagnostic tests. Mark’s recent projects, many supported by the Luminesce Alliance, have improved analysis of children’s cancer data, producing tools to detect features such as non-coding, splicing, mitochondrial and structural mutations.
A/Prof Anai Gonzalez-Cordero
Group Leader Stem Cell Medicine and Head of the Stem Cell & Organoid Facility, Children’s Medical Research Institute
Speaker Bio
Associate Professor Anai Gonzalez-Cordero is a Al & Val Rosenstrauss Fellow, and a Group Leader at Children’s Medical Research Institute (CMRI), The University of Sydney.
Dr Gonzalez-Cordero is a leader in the field of stem cells and their differentiation into organoids with an emphasis on translational research to develop novel therapies for retinal genetic diseases.
Having started her scientific career in the UK, she obtained a Wellcome Trust PhD in Stem Cell and Developmental Biology and continued her work at the Institute of Ophthalmology, University College London. In 2019, Dr Gonzalez-Cordero relocated to Australia to continue her research programme in stem cells and ophthalmology. Her work in the field has led to numerous awards, including the MetCalf Prize for Stem Cell Research in 2022, and high impact studies including proof-of-concept studies for stem cell-based cell therapy by transplantation of the light sensing cells, the photoreceptor cells, which once in the eye can rescue vison perception in blind animal models. At CMRI she also heads the Stem Cell and Organoid Facility proving iPSC lines and human organoid models for Australian researchers.
Professor Tom Snelling
Director of the Health and Clinical Analytics, School of Public Health, University of Sydney, Children’s Hospital at Westmead
Speaker Bio
Professor Tom Snelling is a clinical scientist, Director of Health and Clinical Analytics in the School of Public Health at The University of Sydney, and an infectious diseases physician at Sydney Children’s Hospitals Network. Tom has particular interest in vaccine preventable diseases and application of decision theory to research design. He leads a team of researchers aiming to improve healthcare and reduce the burden of infectious disease by implementing learning health systems.
Tom applies Bayesian approaches to the design, implementation, and analysis of public health studies, and is successfully leading a suite of multi-institutional collaborative projects across Australia covering a range of clinical domains. These include improving treatment and prevention of severe gastroenteritis in remote Aboriginal children, primary prevention of food allergies in children, SMS text messages to improve timeliness of routine immunisation, and improving management of cystic fibrosis.
Professor Louis Chesler
Professor of Childhood Cancer Biology and Therapeutics Executive Director, Children’s Cancer Institute of Australia Co-Director, The Minderoo Comprehensive Children’s Cancer Centre, Sydney Children’s Hospital, Randwick, Australia
Speaker Bio
Professor Louis Chesler was appointed Executive Director of Children’s Cancer Institute in December 2025. He is an internationally highly regarded clinician researcher who has committed his life’s work to discovering new treatments and translating them into clinical practice for children with cancer. Since Louis achieved his post-doctoral fellowship at the National Cancer Institute in Bethesda, Maryland, USA his career has spanned several prestigious appointments at some of the world’s leading childhood cancer research institutes and hospitals.
Initially working as a paediatric oncology consultant whilst leading his neuroblastoma and medulloblastoma research program which focused on targeting the oncogene MYCN at the University of California, San Francisco. Louis is today a Fellow of The Royal College of Paediatrics and Child Health, UK, and for the past nearly 20 years has led the Paediatric Oncology Experimental Medicine (POEM) Centre at the prestigious Institute of Cancer Research (ICR) in London, which is internationally renowned for its breakthroughs in first-in-child therapeutics, its dedication to genomic driven precision medicine trials, and which hosts several flagship research and clinical programmes in the UK including the UK’s national child cancer personalised medicine program known as SM Paeds.
Louis also leads the ICR paediatric Cancer Modelling and Preclinical Therapeutics Hospital, and the Cancer Modelling Programme of the MRC National Mouse Genomics Network, and has an extremely strong interest in immune oncology, with a major focus on developing novel CAR T cells that are moving into clinical trials through international partnerships, as well as undertaking the preclinical modelling of these novel therapies. He is also a Research Group Leader for the Institute of Cancer Research UK and physician at The Royal Marsden NHS Foundation Trust with a particular focus on hard-to-treat childhood cancers.
Louis’ collaborations span the globe, including previously with Children’s Cancer Institute. He has an exceptional track record of research development, generating significant programmatic grant funding, supporting a range of basic, translational and clinical trials initiatives. He is passionate about laboratory research that produces clinical impact and alters delivery of clinical medicine. Louis’s background as a clinician researcher and paediatric oncologist bridges the gap between research and clinical implementation.
Professor Maria Kavallaris AM
Professor and Head of Translational Cancer Nanomedicine NHMRC Investigator Children's Cancer Institute
Speaker Bio
Professor Maria Kavallaris AM is Founding Director of the Australian Centre for NanoMedicine at UNSW Sydney, Head of the Translational Cancer Nanomedicine at the Children’s Cancer Institute, and an NHMRC Investigator. She is internationally recognised for leading interdisciplinary research in cancer nanomedicine and therapeutics. Her research has uncovered key mechanisms of resistance to cancer therapies and translated into patents, industry partnerships, and clinical development of novel therapeutics and devices, including nanoparticle based delivery of gene silencing agents and chemotherapy.
Professor Kavallaris served as Chair of the Australian Institute for Policy and Science and is a Life Member and past President of the Australian Society for Medical Research. She is a Fellow of AAHMS, RSN, CRS and AIMBE, and has received numerous honours, including the Eureka Prize, Premier’s Award for Leadership in Innovation, and appointment as a Member of the Order of Australia.
Professor Matt Dunn OAM
Chair in Medical Sciences and Professor of Paediatric Haematology/Oncology Research at the University of Newcastle
Speaker Bio
Professor Matt Dun OAM is Chair in Medical Sciences and Professor of Paediatric Haematology/Oncology Research at the University of Newcastle, where he leads Brain Cancer Research within the Hunter Medical Research Institute’s Precision Medicine & Health Program and the paediatric stream of the MHF Centre for Brain Cancer Research.
His work focuses on DMG and DIPG, integrating spatial biology, proteogenomics, AI and clinical trials to develop adaptive precision therapies for children with brain cancer.
Matt’s research underpins the international PNOC022 clinical trial (NCT05009992) and has helped define key genetic, metabolic and immune mechanisms driving treatment resistance in DMG.
He has published more than 110 papers and secured over $45 million in competitive, philanthropic and industry funding.
Internationally recognised for his translational impact, Matt has received 38 national and international awards, including the ASMR Medal, the NSW Premier’s Outstanding Cancer Research Fellow Award (Cancer Institute NSW), University of Newcastle and HMRI Mid-Career Researcher of the Year awards, the PNOC Basic Science Trailblazer Award, the International DIPG Big Hero, Innovator and Spirit Awards, the AFR Emerging Leader Award, and the Medal of the Order of Australia (OAM).
Dr Rebecca Poulos
Group Leader (Multi-Omics and Childhood Cancer) and Senior Research Fellow in ProCan at Children’s Medical Research Institute, and a Conjoint Senior Lecturer at the University of Sydney.
Speaker Bio
Dr Rebecca Poulos is a Group Leader (Multi-Omics and Childhood Cancer) and Senior Research Fellow in ProCan at Children’s Medical Research Institute, and a Conjoint Senior Lecturer at the University of Sydney. She has expertise in cancer genomics, proteomics and data science, and leads a translational research lab that uses big data from childhood cancer to understand cancer biology, predict drug response and develop methods for large-scale multi-omic data analysis in childhood cancer. Prior to this, her research focused on cancer genomics, specifically investigating associations between somatic mutations and DNA repair, methylation and gene expression in cancer.
Emma Maly
Full-time mother and carer; and Board Member, ADCY5.org Foundation, Scientific Advisory Board
Speaker Bio
Emma Maly BSN Nursing is the proud full-time mother and carer of ten-year-old Grace and her two older brothers. Emma is helping Grace to reach her fullest potential while she navigates life with ADCY5-Related Movement Disorder.
Emma is a member of the Scientific Advisory Board of ADCY5.org foundation and is passionate about raising awareness of the importance of research for improved health outcomes for those living with rare diseases.
Emma started her professional career as an acute care nurse and then moved to the pharmaceutical and biotechnology industry, working as a Field Education Specialist in psychiatry for Lundbeck Australia, a Specialist Sales Representative in oncology for Mayne Pharmaceuticals, and an Oncology and Field Education and Product Specialist for Amgen Australia. Until recently, she provided preoperative and postoperative care for an Orthopaedic Specialist.
Professor Maria Kavallaris AM
Professor and Head of Translational Cancer Nanomedicine NHMRC Investigator Children's Cancer Institute
Speaker Bio
Professor Maria Kavallaris AM is Founding Director of the Australian Centre for NanoMedicine at UNSW Sydney, Head of the Translational Cancer Nanomedicine at the Children’s Cancer Institute, and an NHMRC Investigator. She is internationally recognised for leading interdisciplinary research in cancer nanomedicine and therapeutics. Her research has uncovered key mechanisms of resistance to cancer therapies and translated into patents, industry partnerships, and clinical development of novel therapeutics and devices, including nanoparticle based delivery of gene silencing agents and chemotherapy.
Professor Kavallaris served as Chair of the Australian Institute for Policy and Science and is a Life Member and past President of the Australian Society for Medical Research. She is a Fellow of AAHMS, RSN, CRS and AIMBE, and has received numerous honours, including the Eureka Prize, Premier’s Award for Leadership in Innovation, and appointment as a Member of the Order of Australia.
Panellists
Professor Sue Woolfenden
Director of Community Paediatrics, Sydney Local Health District, Professor of Community Paediatrics, Central Clinical School, Sydney Medical School, the Faculty of Medicine and Health, University of Sydney, Co-chair Sydney Institute Women, Children and their Families
Speaker Bio
Professor Sue Woolfenden is the Director of Community Paediatrics at Sydney Local Health District (SLHD) and Professor of Community Paediatrics at The University of Sydney. In her clinical, service development and research roles she aims to address child health and health care inequities in Australia and globally through innovative integrated health-social service models including Hubs and care navigation. She has 166 peer review publications and > 16 M funding to support her work. She is the co-chair of the Sydney Health Partners Child and Adolescent Clinical Academic Group and the Sydney Institute for Women, Children and their Families at SLHD. She co-leads the psychosocial platform of the Luminesce Alliance.
Professor Natasha Nassar
Chair in Translational Childhood Medicine, Financial Markets Foundation for Children, The University of Sydney
Speaker Bio
Professor Natasha Nassar is a perinatal and paediatric epidemiologist, the Financial Markets Foundation for Children Chair in Translational Childhood Medicine and NHMRC Investigator Fellow at the Children’s Hospital at Westmead (CHW) Clinical School, The University of Sydney. She is also the Data Lead of the Menzies Centre for Health Policy and Economics and the Charles Perkins Centre Populations Domain Leader with a key role in facilitating population-based research investigating cardiovascular disease, obesity, diabetes and other related conditions across a wide range of disciplines.
Her research takes a lifespan approach that focuses on understanding early life determinants, perinatal care and childhood conditions on long-term child health and well-being. This involves the use data linkage of clinical, registry and administrative birth, state and Commonwealth health and education datasets to establish statewide birth data cohorts that enable longitudinal follow-up of children over time. These linked data platforms have enabled the investigation of real-world clinical and policy questions of health outcomes, wellbeing, health service utilisation and costs to the health system across the lifespan.
Professor Raghu Lingam
Professor in Paediatric Population and Health Services Research UNSW Sydney, Honorary Professor of Population Child Health at Kings College London and the Black Dog Institute (NSW), Consultant Community Paediatrician Sydney Children’s Hospital Network.
Speaker Bio
Professor Raghu Lingam is a distinguished academic in Paediatrics at UNSW Sydney and an Honorary Professor at the Black Dog Institute. He also serves as a Consultant Community and Neurodevelopmental Paediatrician with the Sydney Children’s Hospital Network, working clinically as a Senior Staff Specialist at the Tumbatin Neurodevelopmental Service at Sydney Children’s Hospital, Randwick. His extensive career in the UK includes academic roles at the London School of Tropical Medicine and Hygiene, The Royal Free/UCL, and the Universities of Bristol and Newcastle. With over 30 years of experience in community and developmental paediatrics and child public health, he works closely with children and families facing complex health, social, and developmental challenges.
As the Lead of the Population Child Health and Health Services Research Group at UNSW and Director of the NSW Centre for Child Health Services Research and Innovations (CHRIS) and its national counterpart, Child UnLimited, Professor Lingam is dedicated to advancing translational health research and addressing inequities in child health outcomes. He has authored over 190 publications and secured more than AUD 50 million in research funding in recent years.
Professor Lingam takes a strengths-based, holistic approach in his work, emphasising the unique abilities of young people and their families. His expertise in assessing and managing children with additional developmental needs informs both his research and clinical practice. His clinical interests include Autism, ADHD, Developmental Coordination Disorder (Dyspraxia), Dyslexia, and the intersection of developmental disorders. His contributions to early childhood development are recognised globally, and he has presented on these topics at prestigious forums, including the WHO, New York Academy of Sciences, and European Academy of Childhood Disability.
Professor Ian Street
Director, THerapeutic INnovations for Kids (THINK), Children’s Cancer Institute
Speaker Bio
Professor Ian Street joined Children’s Cancer Institute in 2020 as Director of THerapeutic INnovations for Kids (THINK). A new research initiative within the Institute’s Drug Discovery Centre, THINK provides an end-to-end pipeline of drug discovery and development and is dedicated to generating new therapies for rapid clinical application in children with cancer.
Ian has dedicated his 30+ year career to translational research and small molecule drug discovery. After completing a PhD in chemistry and enzymology at the University of British Columbia, Canada, he took up a postdoctoral appointment in the USA. He then joined Merck Research labs in Montreal and spent the next 11 years working in the pharma/biotech industry in North America and Australia.
In 2001, he accepted an appointment at the Walter and Eliza Hall Institute as Laboratory Head and Deputy Director of the Cellular Growth Factors Cooperative Research Centre, spending the next 20 years working to bridge the gap between ‘researchers with great ideas’ and the technical and commercial realities of converting those ideas into new medicines.
‘Drug discovery fascinates me,’ Ian says. ‘It’s amazing to me that we can design a molecule that, when given in tiny amounts, will not affect 99.99% of the proteins and tissues in the patient’s body, but will seek out its target and inactivate it, halting the course of a disease.’
Ian has established a number of facilities designed to take drug research from bench to bedside, and has participated in over 100 collaborative projects involving Australian and international scientists. In 2007 he co-founded the Cancer Therapeutics Cooperative Research Centre, where he was Chief Scientist for 11+ years, during which time the outcomes of eight projects were licensed to pharmaceutical and biotechnology companies.
In 2022, Professor Street was appointed to Conjoint Professor, Faculty of Medicine and Health at UNSW Sydney, in recognition of his contributions to drug discovery both in Australia and internationally.
Emeritus Professor Leslie White AM
Director, Children’s Cancer Institute.; Member, Children’s Cancer Institute Scientific Advisory Committee and the Minderoo Children's Comprehensive Cancer Centre Subcommittee; Chair, Marketing and Fundraising Subcommittee
Speaker Bio
Emeritus Professor Leslie White has championed the rights and the engagement of children and young people in healthcare settings.
In addition to Luminesce Alliance, Professor White serves on seven not-for-profit boards or organisations relating to children’s health or medical research. He was awarded a Doctor of Science for research contributions related to childhood cancer and holds a Master of Health Administration. In 2007, he received an Order of Australia award for service to medicine, medical administration and the community in the field of paediatrics. Other continuing interests include childhood injury, intellectual disability, health services research and the networking of paediatric services. In 2019, he was awarded a Doctorate of the University (UNSW) honoris causa.
Professor White was appointed the inaugural NSW Chief Paediatrician in September 2010, a position he held until his retirement in 2016. He was Executive Director of Sydney Children’s Hospital from 1995 to 2010, following a clinical and academic career with emphasis on childhood cancer. Other positions have included President of Children’s Hospitals Australasia (1999-2004) and the John Beveridge Professor of Paediatrics (2005-2010). He has over 140 publications and many more abstracts, awards, grants and invited presentations to his name.
A/Prof Antoine de Weck
Group Leader Computational Drug Discovery Biology Group, Children’s Cancer Institute
Speaker Bio
Associate Professor Antoine de Weck is Group Leader at the Children’s Cancer Institute, a Conjoint Associate Professor at UNSW Sydney and the Lead Investigator of the Luminesce Alliance Innovation Project: Treating Childhood Cancers by Small Molecule Mediated Reactivation of Tumour Suppressors.
Antoine joined Children’s Cancer Institute in January 2022 to establish and lead the Computationally Enabled Drug Discovery (CEDD) Group. CEDD is a hybrid (dry and wet) lab focusing on identifying new therapeutic vulnerabilities in childhood cancers, on identifying new or existing compounds capable of targeting those vulnerabilities, and on establishing an early drug discovery pipeline for small molecules targeting RNA.
Antoine’s group is a key capability of THINK (THerapeutic INnovations for Kids), an initiative dedicated to generating new therapies specifically for children with cancer and moving these from the lab to the clinic as quickly as possible. Before joining Children’s Cancer Institute, Antoine worked at the Novartis Institute for BioMedical Research in Switzerland as a computational biologist in oncology.
Dr Kate Hetherington
Post-doctoral Research Fellow/Clinical Psychologist School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, Australia. Team Leader Ethics and Genetics, Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children's Hospital Randwick
Speaker Bio
Dr Kate Hetherington is a Research Fellow and Clinical Psychologist based at the Behavioural Sciences Unit (BSU), School of Clinical Medicine, UNSW Sydney and the Sydney Children’s Hospital, Randwick.
Kate leads the Behavioural Science Unit’s Precision Medicine and Genomics Team, as well as the Luminesce Alliance Psychosocial Enabling Platform, a funding initiative aimed at ensuring the equitable, inclusive, and psychologically safe delivery of paediatric precision medicine. Kate leads several large-scale projects focused on understanding patients’, families’, and health professionals’ experiences of precision medicine and genetic testing for childhood cancer. Her research aims to ensure that the promise of new and emerging treatments is realised, and that patients and professionals have access to the resources and support they need.
Emeritus Professor Richard Henry AM
Sir Lorimer Dods Professor, Faculty of Medicine and Health, Director, Children's Medical Research Institute, Head, Cancer Research Unit, Children’s Medical Research Institute
Speaker Bio
Emeritus Professor Richard Henry AM works as a consultant in health and higher education, following a long and distinguished career in medicine and academic leadership, including as Vice-President and Deputy Vice-Chancellor (Academic) of the University of New South Wales from 2006-2012.
He joined UNSW in 1997 as the Foundation John Beveridge Professor of Paediatrics. He served as head of the School of Paediatrics and then of the School of Women’s and Children’s Health before moving to the role of Senior Associate Dean in the Faculty of Medicine.
Richard was appointed a Member of the Order of Australia in 2007 for service to paediatric medicine as a clinician, researcher, educator and mentor, and serving in a range of roles with professional medical organisations.
He is excited at the prospect of Luminesce Alliance as a paediatric precision medicine powerhouse able to reduce the time it previously took to deliver research findings to patients.
Trent Zimmerman
Director, Corporate Affairs, Alexion Pharmaceuticals Australia
Speaker Bio
Trent Zimmerman is the Director of Corporate Affairs in Australia for Alexion, AstraZeneca’s rare disease group. He is the former Member for North Sydney in the federal parliament and chaired the House of Representatives Standing Committee on Health, Aged Care and Sport between 2015 and 2022. Prior to his parliamentary service, Trent was Deputy CEO of the Tourism and Transport Forum.
Facilitators
Ms Kathryn Greiner AO
Chair Luminesce Alliance Chair – Pennington Institute Chair – Ministerial Advisory Council on Ageing Chair – Lifestart Co-op Ltd Director – Paul Ramsay Foundation Board Director – Relationships Australia (NSW)
Speaker Bio
Kathryn began her career in Social Work and Early Childhood Services and has contributed in a wide range of leadership positions in public and private companies, government bodies and non-profit organizations.
She has also participated in or led inquiries into education, including the Gonski Review and NSW Catholic Funding Review, and led the Review into Retirement Villages in NSW.
Kathryn is passionate about creating a paediatric translational research hub delivering twenty-first-century precision medicine.
As the Chair of Luminesce Alliance Board, Kathryn also brings corporate board experience in media, financial services and services provision.
Professor Michelle Haber AM
Head of the Experimental Therapeutics Group, Children's Cancer Institute
Speaker Bio
Professor Michelle Haber was appointed the inaugural post-doctoral scientist at Children’s Cancer Institute in 1984. She became Director of the Institute in 2000, and was Executive Director from 2003-2025. She holds a conjoint appointment as Professor in the Faculty of Medicine at UNSW Australia. She is co-Group Leader of the Experimental Therapeutics and Molecular Oncology Group.
Michelle has dedicated her entire professional life to improving clinical outcomes for children with cancer. She is one of Australia’s leading translational researchers and has become the face of Australian childhood cancer research internationally. She is world-renowned for her research into the childhood cancers neuroblastoma and leukaemia, which has led not only to key advances in our understanding of these diseases, but also to new clinical approaches that have improved survival rates.
‘Seeing our science make a difference, knowing we are giving hope and changing outcomes, is tremendous motivation,’ says Michelle, who stresses that implementing her research results into clinical trials is paramount. ‘Genuine translation of research outcomes into benefits for kids with cancer is absolutely key to me.’
Michelle is best-known for defining new molecular targets (genes and proteins that drive the growth and aggressive behaviour of cancers) as well as developing new therapies that attack those targets. Highlights of her career to date include working with Professors Norris and Marshall to implement minimal residual disease testing in children with acute lymphoblastic leukaemia (ALL) which led to a doubling of the survival rate of children with high-risk ALL, and driving the development of Zero Childhood Cancer (ZERO), Australia’s first national child cancer personalised medicine program, which is improving outcomes for children with a range of high-risk cancers.
As Head of the Experimental Therapeutics Group, Michelle’s current research focuses on developing effective treatments for children with neuroblastoma, and extending these treatments to other childhood malignancies including brain tumours, leukaemias and sarcomas. She is also actively involved in developing a number of new research areas arising from the world-leading ZERO program.
In 2007, Michelle was appointed a Member of the Order of Australia for her services to science in the field of research into childhood cancer, to scientific education and to the community. The following year, she was awarded an Honorary Doctorate from UNSW for her eminent service to the cancer research community. In 2014, she received the Cancer Institute NSW’s Premier’s Award for Outstanding Cancer Researcher of the Year, in 2015 was appointed an inaugural Fellow of the Australian Academy of Health and Medical Sciences and in 2022 was elected to the distinguished Australian Academy of Science.
A/Prof Grant Logan
Children’s Medical Research Institute, Sydney Medical School Faculty of Medicine and Health, University of Sydney
Dr Michelle Lorentzos
Paediatric Neurologist, Clinical Trials Medical Lead, Head of Neurogenetics Service
Mrs Emma Maly
Parent Advocate
Dr Emily Mould
Children’s Cancer Institute
Dr Gabor Tax
Research Officer in the Translational Drug Testing and Pharmacogenomics Children's Cancer Institute, Conjoint Lecturer in the School of Medicine, UNSW.
Prof Claire Wakefield
Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children’s Hospital Randwick
Dr Shafagh Waters
Scientia Senior Lecturer at UNSW Sydney, Honorary Senior Scientist Sydney Children’s Hospital Randwick
Anne O’Neill
Director, Enterprise, International Partnerships and Clinical Trials, NSW Health
Dr Katarina Ostojic
Research Fellow, The University of Sydney & Adjunct Associate Lecturer, UNSW Sydney
Dr (Elizabeth) Emma Palmer
Clinical Geneticist, Sydney Children's Hospitals Network Randwick, Clinical Senior Lecturer, School of Clinical Medicine, UNSW Medicine & Health Randwick Clinical Campus Discipline of Paediatrics
Dr Julia Warning
A/Director, Advanced Therapeutics Office for Health and Medical Research, NSW Ministry of Health
Alunya Wilkinson
Parent Research Advisor



